Davis Capital Management’s Pacira BioSciences PCRX Stock Holding History

Davis Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51	Buy	+2	New	+$47	﹤0.01%	1208

Other funds holding PCRX

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Robeco Institutional Asset Management

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

Davis Capital Management's PCRX Position: Q2 2026 in Review

Davis Capital Management opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 2 shares worth $51. The stake represents ﹤0.01% of the portfolio and ranks #1208 among its holdings.

41 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Davis Capital Management held 2 shares of Pacira BioSciences worth $51 as of Q2 2026.
Pacira BioSciences was a new Davis Capital Management position in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #1208 holding.
41 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.